An interim analysis of a Phase 3 open label study of the safety and pharmacokinetics of olezarsen in patients with familial chylomicronaemia syndrome (FCS) previously treated with volanesorsen has provided reassuring results.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
